These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23157526)

  • 1. A dangerous combination: Fabry disease and factor V Leiden.
    Niemann M; Weidemann F
    Intern Med J; 2012 Nov; 42(11):1270-1. PubMed ID: 23157526
    [No Abstract]   [Full Text] [Related]  

  • 2. Fabry disease and Factor V Leiden: a potent vascular risk combination.
    Tchan M; Sillence D
    Intern Med J; 2011 May; 41(5):422-6. PubMed ID: 21605293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of thrombosis with anomalies of the inferior vena cava and factor V Leiden.
    Sánchez Fernández GL; Reiss UM; de Alarcón PA
    Pediatr Blood Cancer; 2008 Mar; 50(3):731. PubMed ID: 17514740
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiology patient page. Factor V Leiden.
    Ornstein DL; Cushman M
    Circulation; 2003 Apr; 107(15):e94-7. PubMed ID: 12707252
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is lifetime anticoagulation required in factor V Leiden mutation?].
    Pötzsch B
    Dtsch Med Wochenschr; 2003 Jul; 128(30):1617. PubMed ID: 12884152
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D; Rakicevic L; Kovac M; Radojkovic D
    Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
    [No Abstract]   [Full Text] [Related]  

  • 7. Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
    Santamaría A; Soria JM; Tirado I; Mateo J; Coll I; Souto JC; Fontcuberta J
    Thromb Haemost; 2005 Jun; 93(6):1193-5. PubMed ID: 15968408
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
    Zavala Hernández C; Hernández Zamora E; Martínez Murillo C; Arenas Sordo Mde L; González Orozco AE; Reyes Maldonado E
    Cir Cir; 2010; 78(2):127-32. PubMed ID: 20478113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [APC resistance--most frequent familial thrombophilia].
    Herren S; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):499-501. PubMed ID: 10517118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
    Houghton DE; Sud S; Moll S; Rollins-Raval MA
    Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
    [No Abstract]   [Full Text] [Related]  

  • 11. High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary.
    Balogh I; Póka R; Losonczy G; Muszbek L
    Thromb Haemost; 1999 Nov; 82(5):1555-6. PubMed ID: 10595655
    [No Abstract]   [Full Text] [Related]  

  • 12. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
    Santacroce R; Bossone A; Brancaccio V; Fortina P; Margaglione M
    Thromb Haemost; 2000 Jun; 83(6):963-4. PubMed ID: 10896257
    [No Abstract]   [Full Text] [Related]  

  • 13. [National evaluation of the diagnosis of activated protein C resistance].
    Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
    Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy.
    Gyan E; Darre S; Jude B; Cambier N; Demory JL; Bauters F; Rose C
    Hematol J; 2001; 2(3):210-1. PubMed ID: 11920248
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
    Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Idiopathic intracranial hypertension and factor V Leiden mutation].
    Younes S; Aissi M; Chérif Y; Daoussi N; Boughammoura A; Frih Ayed M; Sfar MH; Jerbi S
    J Mal Vasc; 2014 Jul; 39(4):270-3. PubMed ID: 24908418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral venous thrombosis associated to homozygous factor V Leiden mutation in a female of Syrian origin.
    Mira Y; Alfaro A; Estellés A; Vayá A; Ferrando F; Villa P
    Haematologica; 2002 Jan; 87(1):ELT02. PubMed ID: 11801486
    [No Abstract]   [Full Text] [Related]  

  • 20. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease.
    Gennari L; Blanco AN; Bermejo E; Salviú J; Grosso S; Lazzari MA
    Thromb Haemost; 2000 Jul; 84(1):138-9. PubMed ID: 10928486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.